According to the agreement, Immunome has obtained exclusive rights to a collection of antibodies directed at an undisclosed target.

Vilobelimab, marketed under the brand name Gohibic, has been authorized by the FDA for emergency use but has not yet received full FDA approval for the treatment of COVID-19.

European Medicines Agency Rejects Eisai's Lecanemab for Alzheimer’s Treatment.

It received approval on March 24, 2023, for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in individuals aged 12 years and older.

Aug 1st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Retifanlimab, marketed under the brand name Zynyz, was approved by the FDA on March 22, 2023.

AbbVie revealed that the European Commission has granted approval for SKYRIZI(risankizumab) to be used in adult patients suffering from moderately to severely active ulcerative colitis.

Rezafungin, marketed under the brand name Rezzayo, was approved by the FDA on March 22, 2023.

Chemomab Therapeutics Announces Positive Results in Phase 2 Study: CM-101 Demonstrates Anti-Fibrotic, Anti-Inflammatory, and Anti-Cholestatic Effects in Primary Sclerosing Cholangitis.

The FDA approved Daybue on March 10, 2023, for the treatment of Rett syndrome in adults and children aged 2 years and older.

The FDA has approved BioMarin's BRINEURA® (cerliponase alfa) for treating children under 3 years old with CLN2 disease.

The FDA approved Skyclarys on February 28, 2023, for the treatment of Friedreich's ataxia in adults and teenagers 16 years and older.